Inhibitor of the serine/threonine kinase STK33 (IC50
= 14 nM). Exhibits >700-fold selectivity for STK33 over the structurally related protein kinase A (PKA); also exhibits 550-fold selectivity over Aurora kinase B.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A potent and selective quinoxaline-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells.
Weiwer et al.
ACS Med.Chem.Lett., 2012;3:1034